SCHEMBL24249396

SCHEMBL24249396

O=C(O)/C(O)=C/C(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.50
MAPT P10636 3/20 0.50
NFE2L2 Q16236 1/20 0.50
GPR52 Q9Y2T5 1/20 0.47
ERCC5 P28715 1/20 0.47
FEN1 P39748 1/20 0.47
HAO1 Q9UJM8 1/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
PTPN1 P18031 1/20 0.46
GSK3B P49841 1/20 0.46
TP53 P04637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
HSP90AA1 P07900 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3305728 0.87 NFE2L2 (0.64) SMN1; SMN2MAPTNFE2L2RAB9ANPC1
SCHEMBL3305717 0.87 NFE2L2 (0.64) SMN1; SMN2MAPTNFE2L2RAB9ANPC1
SCHEMBL3305722 0.87 NFE2L2 (0.64) SMN1; SMN2MAPTNFE2L2RAB9ANPC1
SCHEMBL11710569 0.81 SMN1; SMN2 (0.57) SMN1; SMN2MAPTNFE2L2GPR52ERCC5
SCHEMBL9101487 0.80 CYP1A1 (0.50) PTPN1GSK3BCYP1A1CYP1B1
SCHEMBL8512571 0.80 CYP1A1 (0.50) PTPN1GSK3BCYP1A1CYP1B1
SCHEMBL3306429 0.79 LMNA (0.55) NFE2L2GPR52MEN1KMT2AL3MBTL1
SCHEMBL3306434 0.79 LMNA (0.55) NFE2L2GPR52MEN1KMT2AL3MBTL1
SCHEMBL3306440 0.79 LMNA (0.55) NFE2L2GPR52MEN1KMT2AL3MBTL1
SCHEMBL4929674 0.78 NFE2L2 (0.70) SMN1; SMN2MAPTNFE2L2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220048925-A1 Substituted 3,4,12,12a-Tetrahydro-1H-[1,4]Oxazino[3,4-c]Pyrido[2,1-f][1,2,4]Triazine-6,8-dione, Pharmaceutical Composition, Method for the Production and Use Thereof VIRIOM, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048925-A1 Substituted 3,4,12,12a-Tetrahydro-1H-[1,4]Oxazino[3,4-c]Pyrido[2,1-f][1,2,4]Triazine-6,8-dione, Pharmaceutical Composition, Method for the Production and Use Thereof H1-3, H1-5, H1-0 SMN1; SMN2 590/4885MAPT 2466/4885NFE2L2 3962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.